vs
Corbus Pharmaceuticals Holdings, Inc.（CRBP）与REZOLVE AI PLC（RZLV）财务数据对比。点击上方公司名可切换其他公司
REZOLVE AI PLC的季度营收约是Corbus Pharmaceuticals Holdings, Inc.的1.0倍（$1.2M vs $1.2M），REZOLVE AI PLC净利率更高（-1078.8% vs -1159.2%，领先80.4%）
Corbus Pharmaceuticals Holdings, Inc.是一家临床阶段生物制药公司，专注于研发和商业化针对罕见、重度炎症、纤维化及免疫介导疾病的创新靶向疗法，主要在北美等发达市场运营，满足未被充分覆盖患者群体的医疗需求。
REZOLVE AI PLC是总部位于英国的科技企业，开发人工智能驱动的移动互动与即时交易平台，支持用户直接从音频、视频、印刷内容中完成购买，服务欧洲、北美及部分亚太市场的零售、消费品与媒体客户。
CRBP vs RZLV — 直观对比
营收规模更大
RZLV
是对方的1.0倍
$1.2M
净利率更高
RZLV
高出80.4%
-1159.2%
损益表 — Q3 FY2024 vs Q2 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.2M | $1.2M |
| 净利润 | $-13.8M | $-13.0M |
| 毛利率 | — | — |
| 营业利润率 | -1304.0% | -808.4% |
| 净利率 | -1159.2% | -1078.8% |
| 营收同比 | 447.9% | — |
| 净利润同比 | -37.1% | — |
| 每股收益（稀释后） | $-1.15 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CRBPRZLV
| Q2 25 | — | $1.2M | ||
| Q3 24 | $1.2M | — | ||
| Q2 24 | $906.0K | — | ||
| Q1 24 | $-177.0K | — | ||
| Q4 22 | $-641.0K | — | ||
| Q3 22 | $0 | — | ||
| Q2 22 | $-490.3K | — | ||
| Q1 22 | $0 | — |
净利润CRBPRZLV
| Q2 25 | — | $-13.0M | ||
| Q3 24 | $-13.8M | — | ||
| Q2 24 | $-10.0M | — | ||
| Q1 24 | $-6.9M | — | ||
| Q4 22 | $-10.9M | — | ||
| Q3 22 | $-8.8M | — | ||
| Q2 22 | $-13.2M | — | ||
| Q1 22 | $-9.4M | — |
营业利润率CRBPRZLV
| Q2 25 | — | -808.4% | ||
| Q3 24 | -1304.0% | — | ||
| Q2 24 | -1212.8% | — | ||
| Q1 24 | 5436.3% | — | ||
| Q4 22 | 1684.5% | — | ||
| Q3 22 | — | — | ||
| Q2 22 | 2516.6% | — | ||
| Q1 22 | — | — |
净利率CRBPRZLV
| Q2 25 | — | -1078.8% | ||
| Q3 24 | -1159.2% | — | ||
| Q2 24 | -1103.4% | — | ||
| Q1 24 | 3897.4% | — | ||
| Q4 22 | 1697.3% | — | ||
| Q3 22 | — | — | ||
| Q2 22 | 2702.0% | — | ||
| Q1 22 | — | — |
每股收益（稀释后）CRBPRZLV
| Q2 25 | — | — | ||
| Q3 24 | $-1.15 | — | ||
| Q2 24 | $-0.90 | — | ||
| Q1 24 | $-0.83 | — | ||
| Q4 22 | $-2.60 | — | ||
| Q3 22 | $-2.11 | — | ||
| Q2 22 | $-3.18 | — | ||
| Q1 22 | $-2.26 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $159.4M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $150.5M | $-14.3M |
| 总资产 | $164.2M | $80.1M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CRBPRZLV
| Q2 25 | — | — | ||
| Q3 24 | $159.4M | — | ||
| Q2 24 | $147.0M | — | ||
| Q1 24 | $120.1M | — | ||
| Q4 22 | $59.2M | — | ||
| Q3 22 | $66.2M | — | ||
| Q2 22 | $73.3M | — | ||
| Q1 22 | $86.1M | — |
总债务CRBPRZLV
| Q2 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 22 | $21.6M | — | ||
| Q3 22 | $21.2M | — | ||
| Q2 22 | $21.2M | — | ||
| Q1 22 | $21.2M | — |
股东权益CRBPRZLV
| Q2 25 | — | $-14.3M | ||
| Q3 24 | $150.5M | — | ||
| Q2 24 | $125.5M | — | ||
| Q1 24 | $97.0M | — | ||
| Q4 22 | $33.0M | — | ||
| Q3 22 | $41.9M | — | ||
| Q2 22 | $49.5M | — | ||
| Q1 22 | $61.2M | — |
总资产CRBPRZLV
| Q2 25 | — | $80.1M | ||
| Q3 24 | $164.2M | — | ||
| Q2 24 | $152.0M | — | ||
| Q1 24 | $125.7M | — | ||
| Q4 22 | $66.3M | — | ||
| Q3 22 | $73.8M | — | ||
| Q2 22 | $82.1M | — | ||
| Q1 22 | $95.7M | — |
负债/权益比CRBPRZLV
| Q2 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 22 | 0.65× | — | ||
| Q3 22 | 0.51× | — | ||
| Q2 22 | 0.43× | — | ||
| Q1 22 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-13.9M | $-4.9M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流CRBPRZLV
| Q2 25 | — | $-4.9M | ||
| Q3 24 | $-13.9M | — | ||
| Q2 24 | $-8.9M | — | ||
| Q1 24 | $-8.0M | — | ||
| Q4 22 | $-7.5M | — | ||
| Q3 22 | $-7.2M | — | ||
| Q2 22 | $-12.2M | — | ||
| Q1 22 | $-10.6M | — |
自由现金流CRBPRZLV
| Q2 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 22 | — | — | ||
| Q3 22 | — | — | ||
| Q2 22 | — | — | ||
| Q1 22 | $-10.6M | — |
资本支出强度CRBPRZLV
| Q2 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 22 | 0.0% | — | ||
| Q3 22 | — | — | ||
| Q2 22 | 0.0% | — | ||
| Q1 22 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
